Evidence map›Paper›PMID 31897208›Full record

ArticleOncology letters2020

Weiguo Hong, Yan Hu, Zhenping Fan, Rong Gao, Ruichuang Yang, Jingfeng Bi, Jun Hou

Abstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weiguo HongClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Yan HuClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Zhenping FanLiver Disease Center for Cadre Medical Care, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Rong GaoClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Ruichuang YangClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Jingfeng BiClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.
Jun HouClinical Research and Management Center, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated mortality worldwide. Transcription factors (TFs) are crucial proteins that regulate gene expression during cancer progression; however, the roles of TFs in HCC relapse remain unclear. To identify the TFs that drive HCC relapse, the present study constructed co-expression network and identified the Tan module the most relevant to HCC relapse. Numerous hub TFs (highly connected) were subsequently obtained from the Tan module according to the intra-module connectivity and the protein-protein interaction network connectivity. Next, E1A-binding protein p400 (EP400) and TIA1 cytotoxic granule associated RNA binding protein (TIA1) were identified as hub TFs differentially connected between the relapsed and non-relapsed subnetworks. In addition, zinc finger protein 143 (ZNF143) and Yin Yang 1 (YY1) were also identified by using the plugin iRegulon in Cytoscape as master upstream regulatory elements, which could potentially regulate expression of the genes and TFs of the Tan module, respectively. The Kaplan-Meier (KM) curves obtained from KMplot and Gene Expression Profiling Interactive Analysis tools confirmed that the high expression of EP400 and TIA1 were significantly associated with shorter relapse-free survival and disease-free survival of patients with HCC. Furthermore, the KM curves from the UALCAN database demonstrated that high EP400 expression significantly reduced the overall survival of patients with HCC. EP400 and TIA1 may therefore serve as potential prognostic and therapeutic biomarkers.

Indexed as

E1A-binding protein p400gene co-expression networkhepatocellular carcinomaKaplan-Meier survival analysisrelapse free survivalTIA1 cytotoxic granule associated RNA binding proteintranscription factor

Identifiers

PMID31897208
PMCPMC6924164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.